Skip to main content

Table 2 HIV transmission among 43 HIV-infected women who had two deliveries within the study.

From: Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: A cohort study

 

Mother previously nevirapine un-exposed (first delivery)

Mother previously nevirapine exposed (second delivery)

p-value

Socio-demographic variables

   

   Maternal age [mean ± SD]

25.3 ± 4.7

27.3 ± 4.9

< 0.0001

   Primipara [N (%)]

5 (12)

0 (0)

/

HIV-related factors at enrolment

   

   HIV viral load [median copies per ml (IQR)]

30,412 (6,864; 80,557)

18,918 (7,162; 78,152)

0.34

   CD4 cells per μl [median (IQR)]

430 (303, 595)

334 (188, 460)

< 0.0001

   Disease stage III [N (%)]

14 (33)

9 (21)

0.30

   BMI at 1 month post partum [mean ± SD]

21.4 ± 2.8

22.4 ± 3.1

0.007

   Hemoglobin [g/dl] [mean ± SD]

10.7 ± 1.5

11.0 ± 1.4

0.24

   Positive rapid plasma regain test for syphilis [N (%)]

9 (22)

5 (12)

0.22

Obstetric and infant variables

   

   Caesarean sections [N (%)]

2 (5)

0 (0)

/

   Low birth weight [N (%) < 2500 g]

5 (12)

2 (5)

0.45

   Birth weight [mean ± SD]

3029 ± 536

3042 ± 469

0.82

   Preterm delivery [N (%) ≤ 34 weeks of gestation]

5 (12)

8 (19)

0.75

   Sex [N (%) male]

23 (53)

16 (37)

0.14

Nevirapine prophylaxis at current delivery

   

   Maternal dose taken [N (%)]

43 (100)

43 (100)

/

   Infant dose taken [N (%)]

40 (93)

41 (98)

1.0

HIV transmission and infant mortality

   

   Infants HIV positive ≤ day 42 [N (%)]

3 (7)

3 (7)

1.0

   Infants HIV positive or died ≤ day 42 [N (%)]

4 (9)

3 (7)

1.0

  1. Numbers may differ from the total due to missing data